Angelman syndrome treatment ION582 was well tolerated and was found to improve patients’ symptoms, Phase 1/2 trial data showed.
Phase 1/2 study details
The HALOS clinical trial involving ION582 demonstrated favorable safety profiles and symptom reduction in patients. It involved three doses injected into the spinal canal over a three-month period.
Significant improvements reported
Follow-up data indicated that 97% of patients on medium and high doses showed clinically meaningful improvements across multiple domains including communication, cognition, and motor skills.
Future trial plans
Ionis Pharmaceuticals plans to launch a pivotal Phase 3 study in the first half of 2025 to further evaluate ION582 in Angelman syndrome patients and will meet with regulators to discuss trial designs.
Improvements across patient population
Improvements in nonverbal communication and multiple functional domains were reported in a vast majority of patients, with notable enhancements in daily living skills and motor functions.
Encouraging treatment prospects
The promising data from the trial positions ION582 as a potentially transformative treatment for Angelman syndrome, with expectations for it to become a cornerstone of future neurological medication developments.
